Chlorhexidine spray to prevent radiation skin damage during nasopharyngeal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 randomized interventional trial compares topical 2% chlorhexidine spray versus sterile water applied to the head and neck skin during definitive chemoradiotherapy for stage II–III nasopharyngeal carcinoma with N≥1. Patients receive standard radiotherapy (60–70 Gy) with concurrent chemotherapy and are followed for incidence and severity of acute radiation dermatitis and patient-reported quality of life. Key eligibility includes histologically confirmed disease, planned first-course definitive chemoradiotherapy, ability to consent, and no prior prophylactic skin interventions or known chlorhexidine allergy. The trial is conducted at Jiangxi Cancer Hospital with regular on-treatment skin assessments using standardized grading.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Histologically or cytologically confirmed nasopharyngeal carcinoma. Clinical stage II-III disease with N≥1, according to the UICC/AJCC 9th edition. Planned to receive first-course definitive chemoradiotherapy, with a total radiotherapy dose of 60-70 Gy.

Able to communicate and complete study assessments. Willing to participate and able to provide written informed consent. Eligible based on baseline assessments performed before chemoradiotherapy.

Exclusion Criteria:

* History of or current psychiatric disorder, cognitive impairment, or other severe organic disease.

Presence of another concomitant malignancy. Receipt of any other prophylactic intervention for radiation dermatitis. Pre-existing skin disease before chemoradiotherapy. Known hypersensitivity or allergy to chlorhexidine.

Where it's running

• Jiangxi Cancer Hospital
  Nanchang, Jiangxi, China Recruiting

Study contacts

• Study coordinator: Tianzhu Lu, PhD
• Email: lutianzhu2008@163.com
• Phone: +8615270186250

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immunotherapy versus capecitabine maintenance after chemo‑chemoradiotherapy for high‑risk nasopharyngeal cancer

  This test compares PD‑1 immunotherapy maintenance to capecitabine maintenance after chemo‑chemoradiotherapy for people with high‑risk locally advanced nasopharyngeal cancer who responded to initial chemo‑immunotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07392320

• PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation for locally advanced recurrent nasopharyngeal carcinoma

  This phase II trial tests whether immediate or selective re-irradiation after a good response to PD-1 inhibitor plus gemcitabine-cisplatin helps people with locally advanced recurrent nasopharyngeal carcinoma live longer with acceptable side effects.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07332247

• Low-dose radiotherapy with toripalimab and chemotherapy for recurrent or metastatic nasopharyngeal cancer

  This will test whether adding low-dose radiotherapy to toripalimab plus gemcitabine‑cisplatin helps people with recurrent or metastatic nasopharyngeal cancer respond better while staying safe.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07325539

• PD-1 immunotherapy with chemotherapy followed by immediate or delayed local radiation for newly metastatic nasopharyngeal cancer

  This trial tests whether waiting to give local radiotherapy (only if needed) after PD‑1 immunotherapy plus gemcitabine‑cisplatin works as well and causes less toxicity than giving radiotherapy right away for people with newly diagnosed metastatic nasopharyngeal cancer who respond to initial treatment.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 4 other locations · NCT07235319

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.